VSY Biotechnology

vsybiotechnology.com

As VSY Biotechnology we are a progressive and innovative company that focuses on customer satisfaction by creating superior state of the art ophthalmology products designed and manufactured to greatly enhance and improve vision for our wide range of patients around the globe. All our products go through rigorous and comprehensive research and development to ensure manufacturing efficiency and the highest optic quality. With our superior product line and our sterling focus on our customers needs, we at VSY Biotechnology believe that the future could not be clearer.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

OCEAN GENOMICS AND GENINUS TEAM UP TO DEVELOP RNA-BASED BIOMARKERS AND ADVANCE RESEARCH.

Ocean Genomics, Geninus Inc | March 30, 2021

news image

Ocean Genomics (Pittsburgh, PA), a world chief in AI-based gene expression analysis and RNA biomarker development, and Geninus (Seoul, South Korea), a main full-administration genomics laboratory, report an essential association with the end goal of co-creating RNA-based biomarkers and propelling exploration and clinical applications with emergency clinic, scholastic and biotechnology customers. The two organizations will dispatch in Korea Ocean Genomics' high level AI-based t...

Read More

Diagnostics

ZOETIS TO COMPLETE ACQUISITION OF BASEPAWS TO STRENGTHEN ITS PORTFOLIO

Zoetis | June 27, 2022

news image

Zoetis Inc. is the world's largest animal health company committed to providing medicine and vaccinations for pets and livestock. The company announced completing the acquisition of a privately held petcare genetics company, Basepaws, which offers early health risk assessments, genetic tests, and analytics to pet owners. The acquisition was first announced on June 7th. However, the financial terms of the purchase were not disclosed. Basepaws, founded by CEO Anna Skaya in 2017,...

Read More

Industrial Impact

TANGO THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN TNG260 PHASE 1/2 TRIAL IN PATIENTS WITH STK11-MUTANT CANCERS

Globenewswire | July 25, 2023

news image

Tango Therapeutics, Inc. a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial evaluating TNG260 in combination with pembrolizumab in patients with STK11-mutant cancers. TNG260 is a first-in-class inhibitor of the CoREST complex . “The TNG260 phase 1/2 clinical trial is the first trial to use genetic patient selection in c...

Read More

MedTech

PANGIA BIOTECH PLANS EXPANDED MULTI-CANCER EARLY DETECTION LIQUID BIOPSY STUDY

PanGIA Biotech, Inc. | January 05, 2024

news image

PanGIA Biotech, a US based biotechnology company with a mission to develop true liquid biopsy technology that is scalable for global impact, today announced that it is finalizing its three-year, prospective, multicenter, clinical study on prostate cancer liquid biopsy. This announcement comes as the company prepares to launch additional clinical studies in multi-cancer early detection using the PanGIA® Liquid Biopsy Platform. “The PanGIA urine based true liquid biopsy technology ...

Read More
news image

Cell and Gene Therapy

OCEAN GENOMICS AND GENINUS TEAM UP TO DEVELOP RNA-BASED BIOMARKERS AND ADVANCE RESEARCH.

Ocean Genomics, Geninus Inc | March 30, 2021

Ocean Genomics (Pittsburgh, PA), a world chief in AI-based gene expression analysis and RNA biomarker development, and Geninus (Seoul, South Korea), a main full-administration genomics laboratory, report an essential association with the end goal of co-creating RNA-based biomarkers and propelling exploration and clinical applications with emergency clinic, scholastic and biotechnology customers. The two organizations will dispatch in Korea Ocean Genomics' high level AI-based t...

Read More
news image

Diagnostics

ZOETIS TO COMPLETE ACQUISITION OF BASEPAWS TO STRENGTHEN ITS PORTFOLIO

Zoetis | June 27, 2022

Zoetis Inc. is the world's largest animal health company committed to providing medicine and vaccinations for pets and livestock. The company announced completing the acquisition of a privately held petcare genetics company, Basepaws, which offers early health risk assessments, genetic tests, and analytics to pet owners. The acquisition was first announced on June 7th. However, the financial terms of the purchase were not disclosed. Basepaws, founded by CEO Anna Skaya in 2017,...

Read More
news image

Industrial Impact

TANGO THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN TNG260 PHASE 1/2 TRIAL IN PATIENTS WITH STK11-MUTANT CANCERS

Globenewswire | July 25, 2023

Tango Therapeutics, Inc. a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial evaluating TNG260 in combination with pembrolizumab in patients with STK11-mutant cancers. TNG260 is a first-in-class inhibitor of the CoREST complex . “The TNG260 phase 1/2 clinical trial is the first trial to use genetic patient selection in c...

Read More
news image

MedTech

PANGIA BIOTECH PLANS EXPANDED MULTI-CANCER EARLY DETECTION LIQUID BIOPSY STUDY

PanGIA Biotech, Inc. | January 05, 2024

PanGIA Biotech, a US based biotechnology company with a mission to develop true liquid biopsy technology that is scalable for global impact, today announced that it is finalizing its three-year, prospective, multicenter, clinical study on prostate cancer liquid biopsy. This announcement comes as the company prepares to launch additional clinical studies in multi-cancer early detection using the PanGIA® Liquid Biopsy Platform. “The PanGIA urine based true liquid biopsy technology ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us